Adage Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Adage Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.9M	Buy	510,000 +500,000	+5,000%	+$11M	0.02%	658
2026 Q1	$223K	Buy	10,000 +844	+9%	+$20.2K	﹤0.01%	911
2025 Q4	$245K	Sell	9,156 -2,475,000	-100%	-$59.1M	﹤0.01%	877
2025 Q3	$53M	Buy	2,484,156 +1,880,356	+311%	+$44.5M	0.08%	228
2025 Q2	$13M	Buy	+603,800	New	+$11.2M	0.02%	558
2023 Q3	–	Sell	-3,553,093	Closed	-$85.1M	–	863
2023 Q2	$85.1M	Buy	3,553,093 +2,328,093	+190%	+$51.7M	0.18%	132
2023 Q1	$23.1M	Buy	+1,225,000	New	+$23.3M	0.05%	379
2021 Q1	–	Sell	-80,000	Closed	-$4.28M	–	953
2020 Q4	$4.28M	Buy	+80,000	New	+$3.97M	0.01%	703
2016 Q2	–	Sell	-259,800	Closed	-$7.26M	–	681
2016 Q1	$7.26M	Buy	+259,800	New	+$5.66M	0.02%	567

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Adage Capital Partners's ACAD Position: Q2 2026 in Review

Adage Capital Partners increased its Acadia Pharmaceuticals (ACAD) stake by 5,000% in Q2 2026, buying an estimated $11M and bringing the position to 510,000 shares worth $12.9M. The position accounts for 0.02% of the portfolio, ranked #658.

Adage Capital Partners first reported a position in ACAD in Q1 2016 and has held it in 9 quarters since. The position peaked at $85.1M in Q2 2023. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Adage Capital Partners held 510,000 shares of Acadia Pharmaceuticals worth $12.9M as of Q2 2026.
Adage Capital Partners bought 500,000 Acadia Pharmaceuticals shares in Q2 2026, an estimated $11M.
Acadia Pharmaceuticals made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #658 holding.
Adage Capital Partners first reported a position in Acadia Pharmaceuticals in Q1 2016 and has held it in 9 quarters since.
Adage Capital Partners's Acadia Pharmaceuticals position peaked at $85.1M in Q2 2023.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.